Nutraceuticals:

Cold Hyperalgesia – The painful hypersensitivity to cold

This is a clinically important topic given how commonly chronic pain patients report cold weather exacerbating their symptoms.

See: 

 

 

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Cold Hyperalgesia (CH)

Cold Hyperalgesia: Definition and Clinical Significance

Cold hyperalgesia refers to an exaggerated pain response to normally mildly painful cold stimuli, while cold allodynia describes pain evoked by innocuous cooling that would not normally cause pain.[1] These phenomena are common in patients with chronic pain—the majority of chronic pain patients report cold weather worsening their pain. Epidemiological data shows that 67% of studies find associations between weather variables and chronic musculoskeletal pain, with temperature being negatively correlated with osteoarthritis pain intensity.

Yes, increased pain in cold weather can be a manifestation of cold hyperalgesia, a condition where the nervous system becomes overly sensitive to cold, causing an exaggerated pain response, common in neuropathic pain, CRPS, and fibromyalgia. This happens because cold can heighten nerve sensitivity, triggering intense pain signals, even from normally mild temperatures, sometimes due to central sensitization or issues with cold-sensing nerves (TRPM8).

Why Cold Weather Increases Pain:

  • Nerve Sensitivity: Cold temperatures can make nerves more irritable, leading to more intense pain signals for people with chronic conditions.
  • Central Sensitization: A process where the central nervous system becomes hypersensitive, amplifying pain signals from all stimuli, including cold.
  • Muscle & Tissue Tightening: Cold causes muscles and connective tissues to contract, increasing stiffness and pressure on joints.
  • Reduced Circulation: Blood vessels constrict in the cold to preserve core warmth, potentially reducing circulation to extremities and worsening joint pain.

Conditions Often Associated with Cold Hyperalgesia:

  • Neuropathic Pain: Nerve damage conditions like diabetic neuropathy.
  • Complex Regional Pain Syndrome (CRPS): Extreme sensitivity to temperature changes.
  • Fibromyalgia (FM): Lower thresholds for cold-induced pain.
  • Osteoarthritis (OA): Can cause increased pain and stiffness in cold weather.

 

Weather-Related Pain Exacerbation:

A 2025 review specifically addressing ambient temperature’s role in chronic pain syndromes found that patients with fibromyalgia, CRPS, osteoarthritis, and multiple sclerosis all show lower thresholds for cold-induced pain compared to healthy controls.[10]

In fibromyalgia, lower barometric pressure and increased humidity are significantly associated with increased pain intensity, with stress moderating this relationship.[1] Significant individual differences exist—about 17% of patients show the opposite pattern (increased pain with rising barometric pressure).[1]

 

Treatment Options for Cold Hyperalgesia

Treatment absences include oral medications and topical applications. There is little research in humans and apparently no studies that compare the effectiveness between the different treatment options.

Pharmacological Treatments with Evidence:

A systematic review of treatments specifically addressing evoked pain found that tricyclic antidepressants, SNRIs, gabapentinoids, opioids, cannabinoids, lamotrigine, mexiletine, lidocaine gel, and botulinum toxin-A have been shown to relieve cold allodynia in various neuropathic pain conditions.[1]

In a menthol-evoked cold hyperalgesia model in healthy volunteers, tramadol 100 mg significantly reduced cold hyperalgesia (NNT 4.5), while Lyrica (pregabalin) 100 mg and ibuprofen 600 mg were not significantly helpful.[2]

Capsaicin 8% Patch:

Topical high-concentration capsaicin has a unique mechanism relevant to cold hyperalgesia. Activation of TRPV1 afferents by capsaicin reduces sensitivity to cold and cold pain in humans through crosstalk mechanisms.[1] In non-freezing cold injury (a condition characterized by cold-evoked pain), capsaicin 8% patch treatment significantly decreased both spontaneous pain and cold-evoked pain.[3] Importantly, the presence of cold hyperalgesia before treatment predicts response to capsaicin—patients with elevated cold pain threshold z-values showed significantly better outcomes.[4]

  • Capsaicin 8% patch for localized areas — particularly if cold hyperalgesia is present on QST (predicts response)

Nutraceutical Treatments with Evidence

  • Palmitoylethanolamide (PEA)
  • Beta-Caryophyllene
  • Alpha-Lipoic Acid (ALA)
  • Omega-3 Fatty Acids (EPA/DHA):
  • Vitamin D:

Clinical Recommendations

For patients with prominent cold hyperalgesia or cold weather-related pain exacerbation, a multimodal approach targeting the identified mechanisms may be beneficial:

  1. PEA 600 mg BID (ultramicronized)
  2. Alpha-lipoic acid 600 mg daily
  3. Omega-3 fatty acids (EPA/DHA) 2-3 g daily
  4. Vitamin D if suboptimal
  5. Capsaicin 8% patch for localized areas

 

Evidence for Cold Hyperalgesia/Thermal Sensitivity

Palmitoylethanolamide (PEA)

The evidence for PEA specifically targeting cold hyperalgesia is moderate and primarily derived from its effects on thermal sensitization parameters:

The pivotal human RCT by Lang-Illievich et al. (2022) demonstrated that PEA 1200 mg/day for 4 weeks significantly prolonged cold pain tolerance compared to placebo in healthy volunteers.[5] This study also showed PEA reduced wind-up ratio and allodynia distance, indicating effects on both peripheral and central sensitization mechanisms relevant to cold hyperalgesia.

Preclinically, PEA relieves thermal hyperalgesia in the chronic constriction injury model through CB1, PPARγ, and TRPV1 receptors.[6] The mechanism involves the “entourage effect”—PEA inhibits FAAH, increasing anandamide levels, which then modulates TRPV1 activity. Since TRPV1-positive neurons normally suppress cold sensitivity, PEA’s TRPV1 modulation may indirectly affect cold pain processing.[1][6]

PEA also reduces NGF production from mast cells—and NGF is the key driver of TRPA1 upregulation that causes cold hyperalgesia after inflammation and nerve injury.[5][6] This provides a mechanistic rationale for PEA’s potential benefit in cold hyperalgesia.

  • PEA 600 mg BID (ultramicronized) — addresses mast cell/glial activation, NGF, and TRPV1 modulation

Alpha-Lipoic Acid (ALA):

ALA has the most direct evidence for cold hyperalgesia. In a CRPS-I mouse model, repeated ALA treatment (100 mg/kg daily for 15 days) reduced cold allodynia (acetone test) by reducing oxidative stress and neuroinflammation, including decreased spinal astrocyte activation and Nrf2 levels.[7] ALA modulates T-type calcium channels (Cav3.2) in sensory neurons, and locally injected ALA decreased sensitivity to noxious thermal stimuli in wild-type but not Cav3.2 knockout mice.[8] ALA also inhibits TRPV1 channel activity, reducing diabetes-mediated neuropathic pain including hot sensitivity pain.[9]

  • Alpha-lipoic acid 600 mg daily — targets T-type calcium channels and oxidative stress

 

Omega-3 Fatty Acids (EPA/DHA)

Omega-3 supplementation shows promising evidence for thermal hyperalgesia. In a chronic constriction injury model, fish oil enriched in omega-3s (0.72 g/kg) reversed thermal hyperalgesia and reduced mechanical allodynia while promoting nerve regeneration.[10] A 2025 study demonstrated that omega-3-enriched fish oil prevented cold hypersensitivity induced by oxaliplatin, with reduction of spinal cord microglia activation and decreased cytokine/BDNF levels.[1] The mechanism involves TRPV1 modulation—EPA and DHA reversed cold stress-induced changes in TRPV1 signaling in the medial prefrontal cortex, hippocampus, and periaqueductal gray.[2]

  • Omega-3 fatty acids (EPA/DHA) 2-3 g daily — anti-neuroinflammatory, TRPV1 modulation

 

Vitamin D

Vitamin D deficiency induces chronic pain and microglial phenotypic changes, with PEA counteracting both pain behavior and spinal biochemical changes in vitamin D-deficient mice.[3] Cholecalciferol supplementation reduced cold allodynia in a mononeuropathy model, with transcriptomic analysis showing massive gene dysregulation associated with opioid signaling and nociception.[4]

  1. Vitamin D if suboptimal blood levels — addresses microglial dysfunction

Summary Table: Nutraceuticals for Cold Hyperalgesia

Nutraceutical

Evidence Level

Mechanism for Cold/Thermal Pain

Key Findings

References

PEA

Moderate (human RCT)

TRPV1 modulation, NGF reduction, mast cell stabilization

Prolonged cold pain tolerance; reduced thermal hyperalgesia in CCI model

[1], [2]

Alpha-Lipoic Acid

Moderate (preclinical + clinical)

T-type Ca²⁺ channel inhibition, TRPV1 modulation, antioxidant

Reduced cold allodynia in CRPS-I model; reduced thermal sensitivity

[3], [4], [5]

Omega-3 (EPA/DHA)

Moderate (preclinical)

TRPV1 modulation, anti-neuroinflammatory, nerve regeneration

Reversed thermal hyperalgesia; prevented oxaliplatin-induced cold hypersensitivity

[6], [7], [8]

Vitamin D

Low-Moderate (preclinical)

Microglial modulation, opioid signaling

Reduced cold allodynia in mononeuropathy; deficiency induces pain

[9], [10]

PEA + Beta-Caryophyllene combination

Moderate (preclinical)

Multi-target (PPARα, CB2, antioxidant)

Reduced thermal hyperalgesia comparable to gabapentinoids

[1]

Synergies – Combination Treatment Approach

Aside from one study on the commercial product, Noxiall, there is a little research to guide one in selecting, which combination for trial. Assessment of the different mechanisms will provide suggested choices.

Noxiall (PEA + Beta-Caryophyllene + Carnosic Acid + Myrrh):

This commercial combination was efficacious in reducing CCI-induced thermal hyperalgesia with effects comparable to gabapentin and pregabalin, and showed additive efficacy when combined with sub-effective pregabalin doses.[5]

 

 

Physiological Mechanisms of Cold Hyperalgesia

The pathophysiology involves multiple overlapping mechanisms at peripheral, spinal, and supraspinal levels:

Peripheral Mechanisms – TRP Channel Dysregulation:

The primary cold sensors are TRPM8 (activated by innocuous cooling, ~26-31°C threshold) and TRPA1 (activated by noxious cold, <17°C).[1][4] In neuropathic pain states, several changes occur:

– TRPA1 upregulation: Inflammation and nerve injury increase TRPA1 (but not TRPM8) expression in dorsal root ganglion neurons through an NGF-induced, p38 MAPK-dependent pathway. Intrathecal anti-NGF or TRPA1 antisense oligodeoxynucleotides suppress cold hyperalgesia.[5]

– IL-33/ST2 signaling: Recent research (2025) demonstrates that IL-33/ST2 signaling in DRG neurons mediates neuropathic cold pain through downstream TRPM8 activation, identifying a novel therapeutic target.[6]

– Neurogenic inflammation pathway: TRPA1 activation triggers release of CGRP and substance P, which induce cold hypersensitivity via GFRα3 (artemin receptor) and TRPM8 in a sexually dimorphic manner.[7]

Silent Cold-Sensing Neurons:

A landmark 2021 Brain study using in vivo calcium imaging revealed that in neuropathic pain states, normally silent large-diameter neurons become cold-sensitive.[8] These “unmasked” neurons express nociceptor markers (Nav1.8, CGRPα) and respond to noxious mechanical stimuli. Ablating Nav1.8-expressing neurons diminishes cold allodynia. This unmasking can be reproduced in normal mice by blocking Kv1 potassium channels, suggesting that downregulation of the “excitability brake” potassium current IKD is a key mechanism.[8][9]

Sodium Channel Dysfunction:

Changes in axonal excitability indicating sodium channel dysfunction occur in conditions like oxaliplatin-induced neuropathy, where Nav1.6 (not Nav1.7) plays an essential role in cold allodynia through increased excitability of cold-sensitive neurons.[1]

Central Mechanisms:

– Central sensitization: Spinothalamic and cortical neuron sensitization via NMDA receptor-mediated mechanisms contributes to cold hyperalgesia—ketamine reduces paradoxical cold pain in experimental models.[1]

– Disinhibition: Loss of Aδ fibers (which normally inhibit C-polymodal nociceptors) causes cold to be experienced as burning pain. Similarly, disruption of central innocuous cold pathways in the insular cortex disinhibits polymodal nociceptive activation of the anterior cingulate cortex.[1]

– TRPV1-mediated crosstalk disruption: TRPV1-positive neurons normally suppress cold sensitivity; their dysfunction unmasks cold hypersensitivity and increases TRPM8 activity.[1]

 

Summary

  1. PEA 600 mg BID (ultramicronized) — addresses mast cell/glial activation, NGF, and TRPV1 modulation
  2. Alpha-lipoic acid 600 mg daily — targets T-type calcium channels and oxidative stress
  3. Omega-3 fatty acids (EPA/DHA) 2-3 g daily — anti-neuroinflammatory, TRPV1 modulation
  4. Vitamin D repletion if deficient — addresses microglial dysfunction
  5. Capsaicin 8% patch for localized areas — particularly if cold hyperalgesia is present on QST (predicts response)

 

References

  1. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
  2. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Lang-Illievich K, Klivinyi C, Lasser C, et al. Nutrients. 2023;15(6):1350. doi:10.3390/nu15061350.
  3. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Alpha Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide. Lo Verme J, Fu J, Astarita G, et al. Molecular Pharmacology. 2005;67(1):15-9. doi:10.1124/mol.104.006353.
  4. Palmitoylethanolamide: A Natural Compound for Health Management. Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R. International Journal of Molecular Sciences. 2021;22(10):5305. doi:10.3390/ijms22105305.
  5. Pharmacokinetic-Pharmacodynamic Influence of N-Palmitoylethanolamine, Arachidonyl-2′-Chloroethylamide and WIN 55,212-2 on the Anticonvulsant Activity of Antiepileptic Drugs Against Audiogenic Seizures in DBA/2 Mice. Citraro R, Russo E, Leo A, et al. European Journal of Pharmacology. 2016;791:523-534. doi:10.1016/j.ejphar.2016.09.029.
  6. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease. Beggiato S, Tomasini MC, Ferraro L. Frontiers in Pharmacology. 2019;10:821. doi:10.3389/fphar.2019.00821.
  7. A Novel Composite Formulation of Palmitoylethanolamide and Quercetin Decreases Inflammation and Relieves Pain in Inflammatory and Osteoarthritic Pain Models. Britti D, Crupi R, Impellizzeri D, et al. BMC Veterinary Research. 2017;13(1):229. doi:10.1186/s12917-017-1151-z.
  8. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
  9. Palmitoylethanolamide for the Treatment of Pain: Pharmacokinetics, Safety and Efficacy. Gabrielsson L, Mattsson S, Fowler CJ. British Journal of Clinical Pharmacology. 2016;82(4):932-42. doi:10.1111/bcp.13020.
  10. Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.